Connected eye-drop dispenser development to achieve feasibility based on micro-dosing technology
Bubendorf, Switzerland, Wednesday, January 27, 2021 - CIS Pharma has achieved feasibility for its connected eye-drop dispenser by successfully evaluating micro-dosing technology for controlled and precise dispensing of an ophthalmic formulation treating dry eye disease. Uniformity of dispensed drops was achieved at a standard deviation of 1.2% at drop sizes as small as 10ul. CIS Pharma offers a platform of [...]
CIS Pharma demonstrates successful in-vivo biodistribution study for Oncology drug carrier
Bubendorf, Switzerland, Tuesday, December 8, 2020 - CIS Pharma successfully completed the biodistribution study with its polymer carrier technology applied to an antibody radionuclide conjugate (ARC). The conjugate was tested in a SKOvip mouse model, an aggressive form of ovarian cancer. The ARC tested comprised Trastuzumab as a model antibody to which two polymer carriers were conjugated that contained several [...]
CIS Pharma contact lens care solution shows enhanced biocompatibility, unsurpassed concentration of hyaluronic acid and a powerful disinfection complex
Bubendorf, Switzerland, Sunday, December 6, 2020 - CIS Pharma has successful up-scaled the production of its novel contact lens multipurpose and disinfection solution (MPDS) to an industrial setup. The contact lens care solution achieved excellent performance compared to products that are leading the markets. From an efficacy perspective, the antimicrobial performance against various bacteria & fungi was tested according to [...]
CIS Pharma demonstrates in-vitro proof of concept for its ’s Oncology drug delivery technology
Bubendorf, Switzerland, Thursday, October 15, 2020 - CIS Pharma’s drug carrier technology has reached invitro proof of concept. A model antibody (Trastuzumab) was conjugated to two polymer carriers that were loaded with radioactive lucetium-177. The subsequent radioactive cell culture test (LINDMO method) showed that the affinity of CIS Pharma antibody radionuclide conjugate (ARC) to its target was similar compared to [...]
CIS Pharma identifies lead polymer carrier for Oncology
Bubendorf, Switzerland, Thursday, May 14, 2020 - CIS Pharma’s polymer expert team has successfully reached the next milestone in its synthesis of the lead polymer carrier. Both analytical protocols as well as upscaling of the polymer technology has been established. “The quality and scale we have established is more than sufficient to enter into invivo studies” says Dr. Christophe Thommen, [...]
CIS Pharma Corona update
Bubendorf, Switzerland, Thursday, April 2, 2020 - CIS Pharma’s pipeline developments will experience some delay as a result of the Corona lock downs. Our Campus remains fully operational due to adequate space as well as due to efficient hygiene concepts. Unfortunately, some of our development partners had to face more stringent policies. We wish all of our partners to stay [...]
CIS Pharma attends EMSO sarcoma symposium in Milano
Milano, Italy, Monday February 3 to Wednesday February 5, 2020 - CIS Pharma attends the sarcoma symposium of the European Society for Medical Oncology, EMSO, in Milano. The event is a highly specialized meeting bringing together medical minds working on these tumor types. The symposium offered a good platform for CIS Pharma to discuss its oncology pipeline with known oncologists [...]
CIS Pharma team attends the World Economic Forum in Davos
Davos, Switzerland, Thursday, January 23, 2020 – CIS Pharma attends the World Economic Forum in Davos, Switzerland. The main interest is to meet with its tracking technology partner modum.io and to attend the event provenance and transparency held at the Hotel Intercontinental in Davos. Tools against counterfeiting and instruments to create transparency in the value chain are two key areas [...]
CIS Pharma’s polymer-drug carriers successfully loaded with Lu-177 and In-111
Bubendorf, Switzerland, Wednesday, January 8, 2020 - In several laoding experiments Lutetium-177 and Indium-111 were loaded to CIS Pharma’s polymer-drug carriers, at high efficiency reates. Labeling density was close the level of metal chelators contained in the polymer-drug carrier, verifying the diversity that is offered by the polymer-drug carrier approach by loading different numbers of therapeutics to the antibody. Normally, [...]
CIS Pharma PEEK implant program has reached the first milestone
Bubendorf, Switzerland, Thursday, December 12, 2019 - A new method for the modification of PEEK surfaces was established that significantly increases hydrophilicity of the material surface. The novel method is a scalable and convenient process and can be tailored to the desired physical properties of the PEEK surface. In preliminary cell culture experiments the modified PEEK surfaces have shown positive [...]
CIS Pharma’s polymer-drug carriers to load radioisotopes show excellent performance in a multiparameter toxicity study
Bubendorf, Switzerland, Monday, December 9, 2019 - CIS Pharm has tested several of its new polymer-drug carriers to conjugate radionuclides in a multiparameter cytotoxicity study at Cyprotex, a CRO based out of the UK and known for its expertise in ADME-tox. No matter what the loading capacity for radionuclides, the polymer-drug carriers show no toxicity effects in cell culture models [...]
CIS Pharma Christmas event in Arlesheim on ice
Arlesheim, Switzerland, Friday, December 6, 2019 - The team of CIS Pharma sets out on sheer ice, armed with stone and broom. After a short introduction, we are ready to play Curling, the traditional sport from Scotland. Gradually, we know how to handle the 20 kg stones and the competition starts: In two teams we take turns sliding heavy, polished granite [...]
CIS Pharma team attends Asia-Pacific vitreo-retina society congress
Shanghai, China, Friday, November 22, 2019 – CIS Pharma is attending the Asia-Pacific vitreo-retina society congress in Shanghai to meet potential partners for its technologies in eye care during the three-day conference in Shanghai China. The Congress is an established, first rate platform in the Asia-Pacific region for scientific exchange, research and discovery in the field of vitreo-retinal diseases and [...]
CIS Pharma successfully conjugated a model antibody to its polymer-drug carrier comprising radioisotopes
Bubendorf, Switzerland, Friday, November 1, 2019 - Within the scope of the proof-of-concept study at the Paul Scherer Institute, a number of polymer-drug carriers enabling the conjugation of different amounts of radioisotopes, were successfully conjugated to model antibody trastuzumab. The site-directed conjugation of the antibody with different polymer-drug carriers was nearly quantitatively. The required excess of polymer as well as [...]
CIS Pharma and the University of Appplied Sciences present their bio-membrane project at the Nano-Tech Event in Baden
Baden, Switzerland, Tuesday, October 29, 2019 - CIS Pharma and the University of Applied Sciences, FHNW Muttenz, are giving a talk at the Nano-Tech Apèro of the Swiss Nanoscience Institute, SNI. During the annual event scientist from academia and the industry gather to exchange their latest learinings on the field of nanoscience. CIS Pharma presents its recent achievements in project [...]
Actinium announces positive interim results of antibody-radionuclide conjugate Iomab-B pivotal trial
New York, USA, Monday, October 28, 2019 - Actinium Pharmaceuticals Inc. announced key interim findings from the pivotal Phase 3 SIERRA trial of Iomab-B, an antibody-radionuclide conjugate, including feasibility and safety data. The Study of Iomab-B in Elderly Relapse/Refractory Acute Myeloid Leukemia, SIERRA, is a 150-patient, Phase 3 pivotal trial that is studying Iomab-B, Iodine-131 conjgated to apamistamab, compared to [...]
CIS Pharma initiates a proof of concept program for its novel polymer-drug carriers tailored to radioisotopes
Bubendorf, Switzerland, Wednesday, September 5, 2019 - CIS Pharma has signed a research agreement with the Paul Scherer Institute, Switzerland. The program comprises an invitro and invivo program for the conjugation of novel polymer-drug carriers to a model antibody by site-directed conjugation strategy and the labeling with suitable radioisotopes for diagnostic and therapeutic use. The antibody-radionuclide conjugates based on CIS [...]
CIS Pharma summer event at the Rhine Falls
Schaffhausen, Switzerland, Friday, July 19, 2019 - During our Summer Event we take a boat ride along the banks of the Rhine Falls in Schaffhausen. The spectacular falls offers a refreshing spray of water. Next stop is Stein am Rhein, a beautiful town known for its medieval half-timbered houses. By boat we get to Steckborn, a small town on the [...]
FDA approves novel antibody-drug conjugate Polivy
Maryland, USA, Monday, June 10, 2019 - The U.S. Food and Drug Administration granted accelerated approval to Polivy - polatuzumab vedotin-piiq, Roche - in combination with the chemotherapy bendamustine and a rituximab product to treat adult patients with diffuse large B-cell lymphoma (DLBCL) that has progressed or returned after at least two prior therapies. Polivy is a novel antibody-drug conjugate, [...]
CIS Pharma initiates a new R&D program in the field of PEEK implants
Bubendorf, Switzerland, Thursday, April 25, 2019 - In a new research program the surface of PEEK medical implants will modified to enhance osteointegration and soft-tissue compatibility. The modification is targeting the use of PEEK at the at the hard-to-soft-tissue interface such as in dental applications. PEEK or Poly-ether-ether-ketone has been used as an implant material in craniofacial application for several years. [...]
CIS Pharma Christmas event in Bern
Bern, Switzerland, Friday, December 7, 2018 - For the end of year event, the team of CIS Pharma sets out to Bern, the capital of Switzerland. Our city guide Domenico Bernabei carries his heart and soul on his tongue and quickly catches our attention with city anecdotes of the last four centuries. His knowledge and entertainment skills got him featured [...]
CIS Pharma starts collaboration with the Paul Scherer Institute on antibody-radionuclide conjugates
Bubendorf, Switzerland, Thursday, November 22, 2018 - CIS Pharma has identified the group of Prof. Schibli and Dr. Behe from the Paul Scherer Institute, ETH, as potential partners for its antibody-radionuclide conjugate program. A scientific program for CIS Pharma’s synthesis unit was elaborated to develop by Q2/2019 novel polymer-drug carriers compatible with established conjugation technologies at Paul Scherer Institute. Upon [...]
Nordic Nanovectors presents promising Phase 1 study results on its antibody-radionuclide conjugate Betalutin
Philadelphia, USA, Thursday, November 1, 2018 - Betalutin is an antibody-radionuclide conjugate, ARC, representing a combination of lilotomab for targeting CD37, a protein that specifically exists on the surface of non-Hodgkin’s lymphoma cells, with the beta particle-emitting isotope lutetium-177. The radionuclide is immobilized with the help of a metal chelator. During treatment Betalutin is internalized into the cells and its [...]
Novartis successfully completes acquisition of Endocyte and its new antibody-radionuclide conjugate
Zurich, Switzerland, Thursday, October 18, 2018 - Novartis today announced that it has completed the acquisition of Endocyte, Inc., a US-based biopharmaceutical company focused on developing radioligand and CAR-T therapies for cancer treatment. With this Novartis can add the antibody-radionuclide conjugate 177-Lu-PSMA-617, a potential first-in-class therapy in Phase III development for metastatic castration-resistant prostate cancer to its portfolio. Novartis intends [...]
CIS Pharma team attends CPhI Worlwide 2018 in Madrid
Madrid, Spain, Tuesday to Thursday, October 9 to 11, 2018 – CIS Pharma is attending CPhI Worlwide to meet development partners and licensees during the three-day conference in Madrid. The team is setting out to meet face-to-face project partners and to source solutions for their innovation projects. As a number of meetings are scheduled we are kindly asking to confirm [...]